{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:04:55Z","timestamp":1745640295756,"version":"3.40.4"},"reference-count":0,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPI"],"published-print":{"date-parts":[[2022,8,7]]},"abstract":"<jats:p>Globally, the prevalence of chronic coronary syndrome (CCS) increases with age. In India, there is  a rapidly growing burden of coronary artery disease (CAD), which has become the leading cause  of morbidity and mortality. Despite recommended medical therapy, patients with CCS are still at  risk of ischemic events. Currently, dual antiplatelet therapy (DAPT) is recommended in the form of  aspirin and a P2Y12 inhibitor or low dose rivaroxaban in patients with stable CAD and\/or peripheral  artery disease (PAD). A low dose of rivaroxaban in combination with aspirin is a promising approach;  however, for patients who might benefit the most, it still remains a challenge. Clinical trial data  on this new drug was certainly very encouraging, with evidence from the COMPASS trial and  prespecified subgroups of COMPASS trials suggesting that the addition of rivaroxaban to aspirin  was associated with a significantly lower risk of ischemic events, mortality, and tolerable bleeding  profile in patients with CCS and high-risk factors. This combination is cost-effective and generally  well tolerated in patients with CAD and\/or PAD, as well as patients with CCS and multimorbidity  or high-risk populations<\/jats:p>","DOI":"10.5005\/japi-11001-0073","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T05:16:46Z","timestamp":1681190206000},"page":"84-88","source":"Crossref","is-referenced-by-count":0,"title":["Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome"],"prefix":"10.59556","volume":"70","author":[{"given":"Lekha","family":"Adik-Pathak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salil","family":"Shirodkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","published-online":{"date-parts":[[2022,8,1]]},"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:57:26Z","timestamp":1745578646000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/files\/JAPI0073_p84-88.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,1]]},"published-print":{"date-parts":[[2022,8,7]]}},"URL":"https:\/\/doi.org\/10.5005\/japi-11001-0073","relation":{},"ISSN":["0004-5772"],"issn-type":[{"type":"print","value":"0004-5772"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}